Roche wins first immunotherapy approval for breast cancer
Oncologists have a new biologic weapon in their breast cancer-fighting arsenal: Roche just won approval for its PD-L1 drug, Tecentriq, to treat breast cancer. It's the very first immunotherapy to be used for this indication.
The approval was narrow: The drug is to be used only for women with locally advanced or metastatic triple-negative breast cancer expressing PD-L1, the molecule that locks onto PD-1 receptors on the surface of T cells.
Preliminary data show that Tecentriq patients with PD-L1-positive had a median overall survival of 25 months, compared to 15.5 months with chemo-only patients.
Read more.
The approval was narrow: The drug is to be used only for women with locally advanced or metastatic triple-negative breast cancer expressing PD-L1, the molecule that locks onto PD-1 receptors on the surface of T cells.
Preliminary data show that Tecentriq patients with PD-L1-positive had a median overall survival of 25 months, compared to 15.5 months with chemo-only patients.
Read more.
No hay comentarios:
Publicar un comentario